Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori

S Wagner, M Gebel, K Haruma, W Bär, P Lange, J Freise, U Gladziwa, F W Schmidt

Abstract
Fifty nine patients with Helicobacter pylori positive duodenal ulcers that failed to heal after a six week course of treatment with H2 blockers were randomly assigned to one of the following three regimens: (i) bismuth subsalicylate, 600 mg three times daily (n=19), (ii) ranitidine, 300 mg at night (n=20), (iii) bismuth subsalicylate plus ranitidine (n=20). Cumulative ulcer healing rates after four and eight weeks respectively were as follows: bismuth subsalicylate 74% (14/19) and 95% (18/19), ranitidine 40% (8/20) and 65% (13/20), bismuth subsalicylate plus ranitidine 80% (16/20) and 95% (19/20). Bismuth subsalicylate treatment was better than ranitidine at both four and at eight weeks (p<0.05). The clearance rates for H pylori after four weeks were: bismuth subsalicylate 58%, ranitidine 0%, bismuth subsalicylate plus ranitidine 55%. After stopping bismuth therapy bacterial recrudescence frequently occurred. After bismuth treatment 86% (19/22) of ulcers had healed if H pylori had been cleared, whereas only 65% (11/17) had healed if H pylori persisted (NS). This study shows that bismuth subsalicylate is more effective in the treatment of resistant duodenal ulcers than standard dose ranitidine. It may be that suppression of H pylori by bismuth subsalicylate promotes ulcer healing.

Patients with endoscopically proved H2 blocker resistant duodenal ulcers were recruited to the study. A resistant duodenal ulcer was defined as one that failed to heal after at least six weeks' continuous treatment with cimetidine 800 mg daily or ranitidine 300 mg daily. The largest ulcer diameter was not less than 5 mm. The patients did not have complications of peptic ulcer disease, previous gastric surgery, concomitant treatment with ulcerogetic drugs, anti-coagulants, or antibiotics, or any serious chronic disease. Only patients who had not had antibiotic treatment in the previous six months were included.

At initial endoscopy the ulcer size was assessed and antral biopsy specimens were taken for histological examination and H pylori screening. All patients were H pylori positive. Detailed information on duration and age of onset of dyspeptic symptoms, previous drug therapy, previous ulcer complications, and social habits were recorded.

After giving informed verbal consent, patients were randomised by a nurse (to guarantee blindness of the investigators) using given regimens stratified for 63 subjects. Randomisation procedure was accomplished by a computer program. Patients were allocated to receive one of the following three treatment regimens: (i) bismuth subsalicylate (Jatrox) 600 mg three times daily (two chewable tablets half an hour before the three meals); (ii) ranitidine (Zantac) 300 mg at night; (iii) bismuth subsalicylate 600 mg three times daily plus ranitidine 300 mg at night. Treatment began within three days of the initial endoscopy and was continued for four weeks. If healing had occurred after four weeks the treatment was stopped; if not the patient continued on the same regimen for another four weeks. If at the end of eight weeks the ulcer had not healed the patient was withdrawn from the trial and ranitidine 900 mg/day was given. No other medications were allowed during the study period.

Compliance was ascertained by counting the number of remaining tablets at the end of each treatment period. Clinical symptoms were assessed by recording the number and severity of pain episodes on a diary card. Endoscopy and H pylori screening tests were repeated every four weeks during the course of treatment and four weeks after the end of the trial.

Methods
Patients and study design
Between September 1987 and May 1990 out...
specimens were placed in 2 ml phosphate buffered saline at 4°C for bacteriological examination, two were fixed in 10% formalin for histopathology, and one specimen was used for a rapid urease detecting test (CLO-test, Delta West Ltd, Australia). In addition, smears of biopsy specimens were made for cytological examination using Giemsa staining.

**H pylori screening**

*H pylori* status was assessed by bacterial culture, a modified Giemsa stain, and the CLO-test as described previously. Two biopsy specimens were cultured under microaerobic conditions in blood agar base containing 5% horse blood and Skirrow selective supplement for seven days. Cultures were considered positive for *H pylori* if Gram negative, oxidase positive, catalase positive, and urease positive spiral rods were present. The degree of colonisation with *H pylori* was estimated by examination of sections and smears stained with Giemsa and was graded semiquantitatively as follows: 0=no organism; 1=occasional; 2=moderate; 3=large numbers. *H pylori* status was regarded as positive if culture was positive or if the urease test and Giemsa stain were positive.

The term 'clearance' was used if *H pylori* status was negative immediately after stopping treatment. 'Eradication' was used if *H pylori* was absent four weeks after the end of treatment.

**Histopathology**

For histological examinations, formalin fixed biopsy samples were embedded in paraffin and sections (4 μm) were stained with haematoxylin and eosin and Giemsa. Each biopsy specimen was assessed for the presence, type, density and localisation of the inflammatory infiltrate. The degree of activity of gastritis was graded (0–3) by estimating the density of polymorphonuclear leukocyte infiltrates as described previously.

**TABLE I Patient characteristics and treatment schedules**

<table>
<thead>
<tr>
<th></th>
<th>BSS (3×600 mg)</th>
<th>Ranitidine (300 mg)</th>
<th>BSS (3×600 mg) plus ranitidine (300 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n)</td>
<td>19</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>15</td>
<td>13</td>
<td>16</td>
</tr>
<tr>
<td>Median age (yrs)</td>
<td>46</td>
<td>47</td>
<td>43</td>
</tr>
<tr>
<td>Duration of ulcer history (median (yrs))</td>
<td>9</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Smokers (n)</td>
<td>14</td>
<td>13</td>
<td>11</td>
</tr>
<tr>
<td>Pain free (n)</td>
<td>4</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td><em>H pylori</em> positive (n):</td>
<td>19</td>
<td>20</td>
<td>20</td>
</tr>
</tbody>
</table>
| Pretreatment (6 wks):  
Cimetidine 800 mg/day (n) | 14 | 12 | 16 |
| Ranitidine 300 mg/day (n) | 5 | 8 | 4 |

BSS=bismuth subsalicylate.

**TABLE II Ulcer healing rates and Helicobacter pylori status after four and eight weeks’ treatment**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Ulcer healed</th>
<th>H pylori negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4 Weeks</td>
<td>8 Weeks</td>
</tr>
<tr>
<td>BSS</td>
<td>14/19 (74%)</td>
<td>18/19 (95%)</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>8/20 (40%)</td>
<td>15/20 (65%)</td>
</tr>
<tr>
<td>BSS+ranitidine</td>
<td>16/20 (80%)</td>
<td>19/20 (95%)</td>
</tr>
</tbody>
</table>

*p<0.05; BSS= ranitidine and BSS plus ranitidine. BSS=bismuth subsalicylate.

**Statistics**

Statistical analysis was carried out by the χ² test for the evaluation of the healing rates and by the matched pairs Wilcoxon signed rank test for analysis of *H pylori* and gastritis scores. Differences with p values less than 0.05 were considered significant.

**Results**

Four of the 63 patients who entered the trial were lost during follow up (bismuth subsalicylate, n=2, ranitidine, n=1, bismuth subsalicylate plus ranitidine, n=1). Ninety five patients completed the study and their characteristics are shown in Table I. There were no major differences between the three treatment groups. Median age, sex ratio, mean duration of ulcer history, smoking habits, and previous H₂ blocker therapy were comparable (Table I). All patients were *H pylori* positive. No relevant side effects were observed in any treatment group.

Figure 1 summarises the outcome of the patients under the different regimens. After four weeks, ulcer healing had occurred in 74% (14/19) of patients receiving bismuth subsalicylate, in 40% (8/20) of those receiving ranitidine, and in 80% (16/20) of those treated with a combination of both regimens (Table II). In patients with incomplete ulcer healing the same therapeutic regimen was continued for another four weeks. After eight weeks' treatment the cumulative healing percentages were 95% on bismuth subsalicylate, 65% on ranitidine, and 95% on bismuth subsalicylate plus ranitidine. The healing rate on bismuth subsalicylate alone or in combination with ranitidine was significantly higher compared with that on ranitidine, both at four and at eight weeks (p<0.05). There was, however, no significant difference between bismuth subsalicylate as a single agent and in combination with ranitidine. After eight weeks there was no ulcer relapse in patients whose ulcers had healed during a four week course of bismuth subsalicylate while two ulcers relapsed in the ranitidine group.

After four weeks *H pylori* was cleared in 58% of patients receiving bismuth subsalicylate and in 55% of those treated with bismuth subsalicylate plus ranitidine, while none of the patients in the ranitidine group was *H pylori* negative (Table II). At eight weeks only a small group of patients was still negative for *H pylori* (bismuth subsalicylate 21%, bismuth subsalicylate plus ranitidine 20%).

The degree of mucosal infestation with *H pylori* was similar in all treatment groups at trial entry (Fig 2). At four weeks a noticeable reduction in *H pylori* scores was observed in groups treated with bismuth subsalicylate, either alone or in combination with ranitidine. At eight weeks the density of colonisation with *H pylori* increased again in the bismuth groups because treatment had been stopped in the majority of patients whose ulcers had healed after four weeks. In a subgroup of patients who received bismuth subsalicylate for eight weeks *H pylori* scores resembled those at four weeks (data not shown). Ranitidine monotherapy had no significant effect on *H pylori* scores at any time.
In the biopsy specimens of the antrum taken before entry active chronic gastritis was found to a similar extent in all study groups (Fig 3). Gastritis scores fell after four weeks of bismuth subsalicylate and were still somewhat lower at eight weeks in these patients when compared with basal values. In parallel to the H pylori scores, ranitidine monotherapy failed to improve gastric inflammation at any time.

Table III shows ulcer healing in relation to clearance of H pylori in patients treated with bismuth subsalicylate alone or in combination with ranitidine. Ulcer healing was higher after clearing of H pylori in comparison with the permanently infected patients, but this difference did not reach statistical significance (healing rate 86% vs 65%; odds ratio 3.15; NS). Some 65% (11/17) of ulcers healed during a four week course of bismuth (alone or combined with ranitidine) despite persistence of H pylori in gastric mucosa, even though there had been a reduction in the overall bacterial load.

In order to study the efficacy of bismuth subsalicylate in eradicating H pylori, patients were reinvestigated four weeks after stopping bismuth treatment. Thirty patients received bismuth subsalicylate for four weeks, and of these three were still H pylori negative four weeks after completing treatment, resulting in an eradication rate of 10%. Nine patients were treated with bismuth subsalicylate for eight weeks, only one patient (11%) eradicated H pylori in this subgroup.

At trial entry epigastric pain was recorded in 14/19, 16/20, and 14/20 respectively in treatment groups (i), (ii), and (iii). Most patients became asymptomatic after two weeks and there was no difference in the proportion of patients with residual symptoms in the three treatment groups.

Discussion
There is no general agreement on the definition of H2 blocker resistant duodenal ulcers. Since most ulcers heal after six weeks' treatment with...
a standard dose of an H2 blocker, this time
criterion was chosen in the present study for the
definition of a resistant ulcer.7 In our series a
further four week course of treatment with
ranitidine 300 mg was able to heal 40% of the
resistant duodenal ulcers, and 65% were healed
after eight weeks. Therefore, only a small group
of patients is truly resistant to H2 blockers, while
most represent slow ulcer healing.

Our controlled trial shows that bismuth sub-
salicylate is superior to standard dose ranitidine
in the treatment of resistant ulcers. Both at four
and at eight weeks, the healing rate was signifi-
cantly higher with bismuth subsalicylate than
with ranitidine treatment. The combination of
bismuth subsalicylate and ranitidine resulted in
healing rates similar to those with bismuth
subsalicylate alone.

While the efficacy of colloidal bismuth sub-
citrate in the treatment of duodenal ulcers is well
established,8-10 only two reports have addressed
the role of bismuth in the treatment of refractory
duodenal ulcers.11 Lam et al have shown that
tripotassium dicitratobismuthate (120 mg four
times daily) heals cimetidine resistant ulcers
significantly better than high dose cimetidine
(1-6 g/day) (healing rates 85% vs 40%). Similar
results have been obtained by Bianchi Porro et al,
who reported significantly higher healing rates
on tripotassium dicitratobismuthate (120 mg
times daily) than on cimetidine (1-2 g and 2
g). Our study shows for the first time that
bismuth subsalicylate is effective in the treat-
ment of resistant duodenal ulcers. The healing
rates on bismuth subsalicylate in our study are
comparable with those achieved with tripot-
assium dicitratobismuthate in the trials of Lam
et al and Bianchi Porro et al. Thus, the efficacy of
bismuth salts in ulcer healing seems to be related
solely to the bismuth component while the anion
may be of minor importance.

Bismuth salts are site protective agents which
have various cytoprotective properties.11-13
Additionally, they have recently been shown to
exert bactericidal effects on H pylori.14-17 The
present study is the first which attempts to
eucidate the role of H pylori in the healing of
resistant duodenal ulcers. None of the patients
treated with ranitidine cleared H pylori, nor did
they show a decrease in the degree of bacterial
infestation. Some 65% (11/17) of the duodenal
ulcers healed with bismuth subsalicylate despite
persistance of H pylori, although at a decreased
number. Thus, bacterial elimination is not a
prerequisite for healing of resistant duodenal
ulcers.

After four weeks' treatment with bismuth,
hower, 86% (19/22) of ulcers had healed if the
bacterium was cleared, whereas only 65% (11/17)
had healed if H pylori persisted. This difference
did not reach statistical significance due to the
small number of patients but the finding may
lend support to the hypothesis that bacterial
clearance promotes ulcer healing. Recently,
Marshall et al showed that duodenal ulcer heal-
ing is significantly higher in patients in whom
H pylori has been eliminated than in those with
persistent bacterial infection.18 In our study,
14% (3/22) of duodenal ulcers did not heal
despite of clearance of H pylori, suggesting that
clearance of H pylori does not necessarily result
in ulcer healing. It could be, however, that
bacterial eradication is a stronger promoter of
ulcer healing than temporary clearance of
H pylori.

Bismuth treatment reduced the density of
bacterial colonisation of the gastric mucosa, but
there was only a transient clearance of H pylori.
Stopping treatment was frequently associated
with a recurrence of the organism in the gastric

---

TABLE III  Ulcer healing in relation to clearance of H pylori
in patients treated with bismuth subsalicylate alone or in
combination with ranitidine

<table>
<thead>
<tr>
<th></th>
<th>Ulcer healed at 4 weeks</th>
<th>Ulcer not healed at 4 weeks</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>H pylori</em> -ve</td>
<td>19</td>
<td>3</td>
<td>22</td>
</tr>
<tr>
<td><em>H pylori</em> +ve</td>
<td>11</td>
<td>6</td>
<td>17</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>9</td>
<td>39</td>
</tr>
</tbody>
</table>
mucosa showing that eradication of *H. pylori* is a rare event during bismuth treatment. In agreement with previous studies, 17–19 we found a close relation between the grade of chronic gastritis and the degree of infestation of gastric mucosa with *H. pylori*. A reduction in the *H. pylori* score was associated with an improvement in gastric inflammation. Therefore, the difference in ulcer healing rates in patients treated with bismuth vs those treated with ranitidine may be partly a result of an improvement of histology.

The role of *H. pylori* in acute ulcer healing seems to be of less importance than its role in the recurrence of duodenal ulcers. A growing body of evidence has accumulated indicating that eradication of *H. pylori* is associated with a significant reduction in ulcer relapses and may even cure duodenal ulcer disease. 11–19

The causes of H₂ blocker ineffectiveness in acute ulcer healing have not been fully clarified. Inadequate acid suppression has been frequently observed in H₂ antagonist non-responders. 20–23 In addition, almost all H₂ blocker resistant duodenal ulcers can be healed by the potent proton pump inhibitor omeprazole. 24, 25 Therefore, inadequate control of acid secretion by H₂ blockers seems to be an important factor in treatment failures.

In conclusion, our study shows that bismuth subsalicylate is effective in the treatment of H₂ blocker resistant duodenal ulcers. In addition, bismuth subsalicylate is superior to a prolonged administration of standard dose H₂ antagonists. The beneficial effects of bismuth subsalicylate in the treatment of resistant ulcers may result from suppression of *H. pylori* and the associated improvement of gastritis in addition to its well known cytoprotective properties.

Part of this work was presented at the 92nd Meeting of the American Gastroenterological Association in New Orleans, on May 20, 1991, and was published in abstract form: *Gastroenterology* 1991; 100: A180.

---

1 Wormsley KG. Duodenal ulcers which do not heal rapidly. *BMJ* 1984; 289: 1091.
10 Tytgat GNJ. Colloidal bismuth subcitrate in peptic ulcer – A review. *Digestion* 1987; 37 (suppl 2): 5–11.

S Wagner, M Gebel, K Haruma, W Bår, P Lange, J Freise, U Gladziwa and F W Schmidt

Gut 1992 33: 179-183
doi: 10.1136/gut.33.2.179

Updated information and services can be found at:
http://gut.bmj.com/content/33/2/179

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/